Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Wiltrout Website

Robert H. Wiltrout, Ph.D.

Selected Publications
1)  Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Designing phase 0 cancer clinical trials.
Clin. Cancer Res. 14: 3675-82, 2008. [Journal]
2)  Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach VE, Wiltrout RH, Harris CC.
Nitric oxide is a key component in inflammation-accelerated tumorigenesis.
Cancer Res. 68: 7130-6, 2008. [Journal]
3)  Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Mol. Interv. 7: 325-34, 2007. [Journal]
4)  Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials: conceptions and misconceptions.
Cancer journal (Sudbury, Mass.). 14: 133-7, , ,. [Journal]
5)  Alderson KL, Zhou Q, Berner V, Wilkins DE, Weiss JM, Blazar BR, Welniak LA, Wiltrout RH, Redelman D, Murphy WJ.
Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy.
J. Immunol. 180: 2981-8, 2008. [Journal]
6)  Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW.
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Clin. Cancer Res. 13: 1936-46, 2007. [Journal]
7)  Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Compressing drug development timelines in oncology using phase '0' trials.
Nat. Rev. Cancer. 7: 131-9, 2007. [Journal]
8)  Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ.
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
Nat. Med. 13: 354-60, 2007. [Journal]
9)  Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH.
Immunotherapy of cancer by IL-12-based cytokine combinations.
Expert opinion on biological therapy. 7: 1705-21, 2007. [Journal]
10)  Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH.
The CD95 receptor: apoptosis revisited.
Cell. 129: 447-50, 2007. [Journal]
11)  Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH.
Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.
Cancer Res. 66: 11005-12, 2006. [Journal]
12)  Yazawa H, Murakami T, Li HM, Back T, Kurosaka K, Suzuki Y, Shorts L, Akiyama Y, Maruyama K, Parsoneault E, Wiltrout RH, Watanabe M.
Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Cancer Gene Ther. 13: 993-1001, 2006. [Journal]
13)  Shorts L, Weiss JM, Lee JK, Welniak LA, Subleski J, Back T, Murphy WJ, Wiltrout RH.
Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
J. Immunol. 176: 6543-52, 2006. [Journal]
14)  Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH.
Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.
Cell. Immunol. 235: 145-52, 2005. [Journal]
15)  Ortaldo JR, Winkler-Pickett RT, Bere EW, Watanabe M, Murphy WJ, Wiltrout RH.
In Vivo Hydrodynamic Delivery of cDNA Encoding IL-2: Rapid, Sustained Redistribution, Activation of Mouse NK Cells, and Therapeutic Potential in the Absence of NKT Cells.
J Immunol. 175: 693-9, 2005. [Journal]
16)  Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW, Murphy WJ, Wiltrout RH.
Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
J Immunol. 172: 943-53, 2004. [Journal]
17)  Gamero AM, Young HA, Wiltrout RH.
Inactivation of Stat3 in tumor cells; Releasing a brake on immune responses against cancer?.
Cancer Cell. 5: 111-2, 2004. [Journal]
18)  Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, Haines D, Laubach VE, Wiltrout RH, Djurickovic D, Harris CC.
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.
Cancer Research. 64: 6849-53, 2004. [Journal]
19)  Welniak LA, Shorts L, Subleski J, Blazar BR, Wiltrout RH, Murphy WJ.
Tumor regression by anti-CD40 and interleukin-2: Role of CD40 on hematopoietic cells and organ-specific effects.
Biol Blood and Bone Marrow Transp. 10: 534-539, 2004. [Journal]
20)  Cataisson C, Joseloff E, Murillas R, Wang A, Atwell C, Torgerson S, Gerdes M, Subleski J, Gao JL, Murphy PM, Wiltrout RH, Vinson C, Yuspa SH.
Activation of cutaneous protein kinase Calpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways.
J Immunol. 171: 2703-13, 2003. [Journal]
21)  Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH.
Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.
Apoptosis. 8: 151-60, 2003. [Journal]
22)  Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH.
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
J Immunol. 170: 2727-33, 2003. [Journal]
23)  Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ.
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Cancer Res. 63: 207-13, 2003. [Journal]
24)  Hixon JA, Anver MR, Blazar BR, Panoskaltsis-Mortari A, Wiltrout RH, Murphy WJ.
Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut.
Biol. Blood Marrow Transplant. 8: 316-25, 2002. [Journal]
25)  Akiyama Y, Maruyama K, Nara N, Hojo T, Cheng JY, Mori T, Wiltrout RH, Yamaguchi K.
Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters.
Cancer Lett. 184: 37-47, 2002. [Journal]
26)  Wigginton JM, Wiltrout RH.
IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside.
Expert Opin Biol Ther. 2: 513-24, 2002. [Journal]
27)  Wigginton JM, Lee JK, Wiltrout TA, Alvord WG, Hixon JA, Subleski J, Back TC, Wiltrout RH.
Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2.
J Immunol. 169: 4467-74, 2002. [Journal]
28)  Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
J Immunol. 168: 3484-92, 2002. [Journal]
29)  Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ.
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation.
Biol. Blood Marrow Transplant. 7: 136-43, 2001. [Journal]
30)  Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrout RH.
Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
J Immunol. 166: 1156-68, 2001. [Journal]
31)  Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH.
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
J Clin Invest. 108: 51-62, 2001. [Journal]
32)  Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH.
Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.
Cancer Res. 61: 6255-63, 2001. [Journal]
33)  Park JW, Gruys ME, McCormick K, Lee JK, Subleski J, Wigginton JM, Fenton RG, Wang JM, Wiltrout RH.
Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).
J Immunol. 166: 3763-70, 2001. [Journal]
34)  Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
J Exp Med. 193: 661-70, 2001. [Journal]
35)  Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Wiltrout RH.
IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.
J Immunol. 164: 231-9, 2000. [Journal]
36)  Wiltrout RH.
Regulation and antimetastatic functions of liver-associated natural killer cells.
Immunol Rev. 174: 63-76, 2000. [Journal]
37)  Lee JK, Back TC, Komschlies KL, Ruscetti FW, Young HA, Wiltrout RH.
Hematopoietic switch from lymphoid to granulocytic development in 3LL tumor-bearing mice.
In Vivo. 15: 255-63, , ,. [Journal]
38)  Welniak LA, Blazar BR, Wiltrout RH, Anver MR, Murphy WJ.
Role of interleukin-12 in acute graft-versus-host disease(1).
Transplant. Proc. 33: 1752-3, , ,. [Journal]
39)  Ortaldo J, Wiltrout R, inventor; DHHS, assignee.
Treatment Of Disorders Associated With Natural Killer T Cells.
Patent Pending, Filed in 2002. Pending [Patent]
40)  Murphy W, Wiltrout R, Blazar B, Wilson S, inventor; DHHS, assignee.
Use of a Promoter of T-Cell Expansion and an Inducer of CD40 Stimulation in the Treatment or Prevention of a Pathologic State.
US Patent: 7,175,838. 2007. [Patent]

This page was last updated on 9/3/2008.